TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Interaction Details
01. General Information
Pair Name Atractylenolide I, Cabozantinib
Phytochemical Name Atractylenolide I (PubChem CID: 5321018 )
Anticancer drug Name Cabozantinib (PubChem CID: 25102847 )
Structure of
Phytochemical		 2D-img
Download
2D MOL 3D MOL
Structure of
Anticancer Drug		 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Enhancing Drug Efficacy
Hide/Show
Combination Pair ID: 1031
Ref_1
Pair Name Atractylenolide I, Cabozantinib
Disease Info [ICD-11: 2C82.0] Prostate cancer Investigative
Biological Phenomena Induction-->Apoptosis
Gene Regulation Up-regulation Expression CASP3 hsa836
Up-regulation Expression BAX hsa581
Up-regulation Expression PARP1 hsa142
Down-regulation Expression BCL2 hsa596
Up-regulation Expression CDH1 hsa999
Down-regulation Expression VIM hsa7431
In Vitro Model DU145 Prostate carcinoma Homo sapiens (Human) CVCL_0105
PC-3 Prostate carcinoma Homo sapiens (Human) CVCL_0035
Result Silencing Hsp27 inhibits EMT. ATL-1 can inhibit the malignant evolution of prostate cancer cells by inhibiting Hsp27/eIF4E. ATL-1 also enhanced chemosensitization of cabozantinib in prostate cancer.
03. Reference
No. Title Href
1 Atractylenolide I inhibits EMT and enhances the antitumor effect of cabozantinib in prostate cancer via targeting Hsp27. Front Oncol. 2023 Jan 6;12:1084884. doi: 10.3389/fonc.2022.1084884. Click
It has been 525666 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP